Prenatal
Secure Natal (NIPT)
Screens for trisomy 21, 18 and 13 from a maternal blood draw.
cfDNA screening for the common trisomies (21/18/13); a screening test that requires confirmation.
- Specimen
- Maternal blood (early gestation)
- Methodology
- cfDNA analysis (NGS)
- Category
- Prenatal
Pricing is available through your BioBloom portal or on request.
This test requires genetic counselling and written consent — your clinic will confirm this at ordering.
How it works
- 1
Order
Place the order through the BioBloom portal.
- 2
Sample
Collect the sample — Maternal blood (early gestation).
- 3
Analysis
Laboratory analysis — cfDNA analysis (NGS).
- 4
Report
Secure report delivered to your clinic through the portal.
What’s in the report
Screening risk for trisomy 21/18/13 (± sex chromosomes and fetal sex); confirmation advised if high-risk.
Research & evidence
Well-established; prenatal exome maturingPrenatal
cfDNA/NIPT is a highly accurate screening test for the common trisomies. Microarray and QF-PCR are first-line diagnostics on invasive samples, with prenatal exome adding yield in selected cases.
Limitations: cfDNA/NIPT is a screening test, not a diagnosis: a high-risk result requires confirmatory invasive testing, and performance for microdeletions is more limited than for the common trisomies.
Read the researchMore in Prenatal
Fetal Karyotype
Full chromosome analysis of the baby.
Array-CGH (microarray)
Detects missing or extra chromosome pieces.
QF-PCR
Rapid check for the most common chromosome conditions.
Whole-Exome Sequencing
Deep gene sequencing to find a suspected genetic cause.
